Terumo to Showcase BSD's MicroThermX® Microwave Ablation System at CIRSE – World's Largest Interventional Radiology Conference *Over 6,000 medical professionals from 85 countries attend CIRSE *Terumo sponsoring focused training sessions for all Terumo sales representatives to capitalize on MicroThermX sales during the conference *Terumo is placing MicroThermX systems with key physician opinion leaders throughout Europe *Some of the world's leading experts in ablation will give presentations on MicroThermX Business Wire SALT LAKE CITY -- September 4, 2013 BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, will showcase BSD's MicroThermX^® Microwave Ablation System (MicroThermX) at the annual Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conference. CIRSE, which will be held in Barcelona, Spain, on September 14-18, 2013, is the world's largest and most prestigious conference in the field of minimally invasive image-guided therapies. In preparation for CIRSE, Terumo is sponsoring focused training sessions for all Terumo sales representatives to ensure they are prepared to capitalize on MicroThermX sales during the conference. As part of the overall sales strategy for the conference, Terumo is placing MicroThermX systems with key physician opinion leaders throughout Europe. Terumo will also send MicroThermX promotional material to all conference attendees. Over 6,000 medical professionals from 85 countries attend CIRSE, reflecting the global impact of the rapidly expanding field of interventional radiology. Terumo is also sponsoring a symposium at CIRSE highlighting the advantages of the MicroThermX. The symposium will feature three presentations focused solely on MicroThermX. "Microwave for lung tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings" will be presented by Professor Philippe Pereira. "Microwave for liver tumour ablation: potential advantages compared with radiofrequency ablation and clinical settings" will be presented by Dr. Laura Crocetti. "Lessons from Microwave ablation with MicroThermX™: why, when, where and how" will be presented by Dr. Damian Dupuy. Professor Pereira and Drs. Crocetti and Dupuy are leading experts in the field of interventional oncology. "We are excited to announce that Terumo will focus on the MicroThermX at CIRSE, the largest interventional oncology conference in the world. Terumo's aggressive marketing strategy should allow them to capture a significant share of the rapidly growing interventional oncology market," said Harold Wolcott, BSD President and CEO. "BSD’s exclusive distribution agreement with Terumo Europe NV for 100 countries represents one of the most significant milestones in our corporate history. The potential market size for thermal ablation in these countries is estimated to be in excess of $1 billion in annual sales." About Terumo Corporation A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology. About the MicroThermX^® Microwave Ablation System The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation. The MicroThermX includes innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue (tumor) ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermX in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX to a number of international markets. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information. Contact: BSD Medical Corporation William Barth, 801-972-5555 firstname.lastname@example.org fax: 801-972-5930
Terumo to Showcase BSD's MicroThermX® Microwave Ablation System at CIRSE – World's Largest Interventional Radiology
Press spacebar to pause and continue. Press esc to stop.